{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:05:52Z","timestamp":1794254752666,"version":"4.9.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010653","name":"Masarykova Univerzita","doi-asserted-by":"publisher","award":["MUNI\/A\/1587\/2023"],"award-info":[{"award-number":["MUNI\/A\/1587\/2023"]}],"id":[{"id":"10.13039\/501100010653","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University Hospital Brno","award":["FNBr, 65269705"],"award-info":[{"award-number":["FNBr, 65269705"]}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["AZV NU21-03-00076"],"award-info":[{"award-number":["AZV NU21-03-00076"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["Programme EXCELES, ID Project No. LX22NPO5102"],"award-info":[{"award-number":["Programme EXCELES, ID Project No. LX22NPO5102"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Div"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Multiple myeloma (MM) represents the second most common hematological malignancy characterized by the infiltration of the bone marrow by plasma cells that produce monoclonal immunoglobulin. While the quality and length of life of MM patients have significantly increased, MM remains a hard-to-treat disease; almost all patients relapse. As MM is highly heterogenous, patients relapse at different times. It is currently not possible to predict when relapse will occur; numerous studies investigating the dysregulation of non-coding RNA molecules in cancer suggest that microRNAs could be good markers of relapse.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Using small RNA sequencing, we profiled microRNA expression in peripheral blood in three groups of MM patients who relapsed at different intervals. In total, 24 microRNAs were significantly dysregulated among analyzed subgroups. Independent validation by RT-qPCR confirmed changed levels of miR-598-3p in MM patients with different times to relapse. At the same time, differences in the mass spectra between groups were identified using matrix-assisted laser desorption\/ionization time of flight mass spectrometry. All results were analyzed by machine learning.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Mass spectrometry coupled with machine learning shows potential as a reliable, rapid, and cost-effective preliminary screening technique to supplement current diagnostics.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13008-025-00143-3","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T06:12:00Z","timestamp":1738131120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Detection of early relapse in multiple myeloma patients"],"prefix":"10.1186","volume":"20","author":[{"given":"Tereza","family":"R\u016f\u017ei\u010dkov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Vlachov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luk\u00e1\u0161","family":"Pe\u010dinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Brychtov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Ve\u010de\u0159a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Radov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"\u0160ev\u010d\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Jaro\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Havel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lud\u011bk","family":"Pour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7194-6771","authenticated-orcid":false,"given":"Sabina","family":"\u0160ev\u010d\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"issue":"9","key":"143_CR1","doi-asserted-by":"publisher","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","volume":"25","author":"H Ludwig","year":"2020","unstructured":"Ludwig H, Novis Durie S, Meckl A, Hinke A, Durie B. Multiple myeloma incidence and Mortality around the Globe; interrelations between Health Access and Quality, Economic resources, and patient empowerment. Oncologist. 2020;25(9):e1406\u201313.","journal-title":"Oncologist"},{"issue":"1","key":"143_CR2","first-page":"3","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci Basel Switz. 2021;9(1):3.","journal-title":"Med Sci Basel Switz"},{"issue":"8","key":"143_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086\u2013107.","journal-title":"Am J Hematol"},{"issue":"12","key":"143_CR4","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u2013548.","journal-title":"Lancet Oncol"},{"key":"143_CR5","doi-asserted-by":"crossref","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA et al. Diagnosis and Management of Multiple Myeloma: A Review. JAMA [Internet]. 2022 Feb 1 [cited 2024 Jul 9];327(5):464. Available from: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2788522","DOI":"10.1001\/jama.2022.0003"},{"key":"143_CR6","doi-asserted-by":"crossref","unstructured":"Ludwig H, Terpos E, Van De Donk N, Mateos MV, Moreau P, Dimopoulos MA et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol [Internet]. 2023 Jun [cited 2024 Oct 10];24(6):e255\u201369. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204523001596","DOI":"10.1016\/S1470-2045(23)00159-6"},{"key":"143_CR7","doi-asserted-by":"publisher","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol [Internet]. 2020 May [cited 2024 Jun 3];95(5):548\u201367. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/ajh.25791","DOI":"10.1002\/ajh.25791"},{"key":"143_CR8","doi-asserted-by":"crossref","unstructured":"Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O et al. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia [Internet]. 2016 May [cited 2024 Nov 5];30(5):1005\u201317. Available from: https:\/\/www.nature.com\/articles\/leu2015356","DOI":"10.1038\/leu.2015.356"},{"key":"143_CR9","doi-asserted-by":"crossref","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol [Internet]. 2016 Aug [cited 2024 Oct 15];17(8):e328\u201346. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204516302066","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"143_CR10","doi-asserted-by":"crossref","unstructured":"Lee JH, Kim SH. Treatment of relapsed and refractory multiple myeloma. BLOOD Res [Internet]. 2020 Jul 31 [cited 2024 Oct 15];55(S1):S43\u201353. Available from: http:\/\/www.bloodresearch.or.kr\/journal\/view.html?doi=10.5045\/br.2020.S008","DOI":"10.5045\/br.2020.S008"},{"key":"143_CR11","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood [Internet]. 2011 May 5 [cited 2024 Oct 15];117(18):4691\u20135. Available from: https:\/\/ashpublications.org\/blood\/article\/117\/18\/4691\/21394\/Consensus-recommendations-for-the-uniform","DOI":"10.1182\/blood-2010-10-299487"},{"key":"143_CR12","doi-asserted-by":"crossref","unstructured":"Bhatt P, Kloock C, Comenzo R. Relapsed\/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol [Internet]. 2023 Feb 15 [cited 2024 Oct 10];30(2):2322\u201347. Available from: https:\/\/www.mdpi.com\/1718-7729\/30\/2\/179","DOI":"10.3390\/curroncol30020179"},{"key":"143_CR13","doi-asserted-by":"publisher","unstructured":"Lu Q, Yang D, Li H, Niu T, Tong A. Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed [Internet]. 2024 Jul 4 [cited 2024 Jul 9];5(1):25. Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1186\/s43556-024-00188-w","DOI":"10.1186\/s43556-024-00188-w"},{"issue":"5","key":"143_CR14","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.1002\/jcp.27486","volume":"234","author":"K Saliminejad","year":"2019","unstructured":"Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451\u201365.","journal-title":"J Cell Physiol"},{"key":"143_CR15","doi-asserted-by":"crossref","unstructured":"Gregorova J, Vychytilova-Faltejskova P, Sevcikova S. Epigenetic Regulation of MicroRNA Clusters and Families during Tumor Development. Cancers [Internet]. 2021 Mar 16 [cited 2024 Oct 10];13(6):1333. Available from: https:\/\/www.mdpi.com\/2072-6694\/13\/6\/1333","DOI":"10.3390\/cancers13061333"},{"key":"143_CR16","doi-asserted-by":"crossref","unstructured":"Vlachov\u00e1 M, Gregorov\u00e1 J, Vychytilov\u00e1-Faltejskov\u00e1 P, Gab\u0142o NA, Radov\u00e1 L, Posp\u00ed\u0161ilov\u00e1 L et al. Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma. Int J Mol Sci [Internet]. 2022 Nov 25 [cited 2024 Jun 3];23(23):14765. Available from: https:\/\/www.mdpi.com\/1422-0067\/23\/23\/14765","DOI":"10.3390\/ijms232314765"},{"key":"143_CR17","doi-asserted-by":"crossref","unstructured":"Wang W, Corrigan-Cummins M, Barber EA, Saleh LM, Zingone A, Ghafoor A et al. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. J Mol Diagn [Internet]. 2015 Nov [cited 2024 Oct 10];17(6):669\u201378. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152515781500152X","DOI":"10.1016\/j.jmoldx.2015.06.006"},{"key":"143_CR18","doi-asserted-by":"publisher","unstructured":"Papadimitriou MA, Soureas K, Papanota AM, Tsiakanikas P, Adamopoulos PG, Ntanasis-Stathopoulos I et al. miRNA-seq identification and clinical validation of CD138\u2009+\u2009and circulating miR-25 in treatment response of multiple myeloma. J Transl Med [Internet]. 2023 Apr 6 [cited 2024 Oct 10];21(1):245. Available from: https:\/\/translational-medicine.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12967-023-04034-5","DOI":"10.1186\/s12967-023-04034-5"},{"key":"143_CR19","doi-asserted-by":"publisher","unstructured":"Zhao G, Jing X, Li Z, Wu X, Gao Z, Ma R. The diagnostic and prognostic values of circulating miRNA-1246 in multiple myeloma. Hematology [Internet]. 2022 Dec 31 [cited 2024 Oct 10];27(1):778\u201384. Available from: https:\/\/www.tandfonline.com\/doi\/full\/https:\/\/doi.org\/10.1080\/16078454.2022.2095890","DOI":"10.1080\/16078454.2022.2095890"},{"key":"143_CR20","doi-asserted-by":"crossref","unstructured":"Kupec T, Bleilevens A, Iborra S, Najjari L, Wittenborn J, Maurer J, PLOS ONE [Internet]. Stability of circulating microRNAs in serum. Roemer K, editor. 2022 Aug 31 [cited 2024 Oct 15];17(8):e0268958. Available from: https:\/\/dx.plos.org\/10.1371\/journal.pone.0268958","DOI":"10.1371\/journal.pone.0268958"},{"key":"143_CR21","doi-asserted-by":"crossref","unstructured":"Liu S, Cheng L, Fu Y, Liu BF, Liu X. Characterization of IgG N-glycome profile in colorectal cancer progression by MALDI-TOF-MS. J Proteomics [Internet]. 2018 Jun [cited 2024 Oct 15];181:225\u201337. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874391918301854","DOI":"10.1016\/j.jprot.2018.04.026"},{"key":"143_CR22","doi-asserted-by":"publisher","unstructured":"Teunissen C, Koel-Simmelink M, Pham T, Knol J, Khalil M, Trentini A et al. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Mult Scler J [Internet]. 2011 Jul [cited 2024 Oct 15];17(7):838\u201350. Available from: https:\/\/journals.sagepub.com\/doi\/https:\/\/doi.org\/10.1177\/1352458511399614","DOI":"10.1177\/1352458511399614"},{"key":"143_CR23","doi-asserted-by":"crossref","unstructured":"Duncan M, DeMarco ML. MALDI-MS: Emerging roles in pathology and laboratory medicine. Clin Mass Spectrom [Internet]. 2019 Aug [cited 2024 Oct 15];13:1\u20134. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S237699981930008X","DOI":"10.1016\/j.clinms.2019.05.003"},{"key":"143_CR24","doi-asserted-by":"crossref","unstructured":"Deulofeu M, Kol\u00e1\u0159ov\u00e1 L, Salvad\u00f3 V, Mar\u00eda Pe\u00f1a-M\u00e9ndez E, Alm\u00e1\u0161i M, \u0160tork M et al. Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma. Sci Rep [Internet]. 2019 May 28 [cited 2024 Oct 15];9(1):7975. Available from: https:\/\/www.nature.com\/articles\/s41598-019-44215-1","DOI":"10.1038\/s41598-019-44215-1"},{"key":"143_CR25","doi-asserted-by":"crossref","unstructured":"Eveillard M, Korde N, Ciardiello A, Diamond B, Lesokhin A, Mailankody S et al. Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy. Clin Chim Acta [Internet]. 2021 May [cited 2024 Oct 15];516:136\u201341. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898121000371","DOI":"10.1016\/j.cca.2021.01.021"},{"key":"143_CR26","doi-asserted-by":"crossref","unstructured":"Gregorova J, Vychytilova-Faltejskova P, Kramarova T, Knechtova Z, Almasi M, Stork M et al. Proteomic analysis of the bone marrow microenvironment in extramedullary multiple myeloma patients. Neoplasma [Internet]. 2022 [cited 2024 Jun 3];69(02):412\u201324. Available from: http:\/\/www.elis.sk\/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7523&category_id=180&option=com_virtuemart","DOI":"10.4149\/neo_2021_210527N715"},{"key":"143_CR27","doi-asserted-by":"crossref","unstructured":"Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, International Myeloma Working Group Mass Spectrometry Committee Report. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an. Blood Cancer J [Internet]. 2021 Feb 1 [cited 2024 Oct 15];11(2):24. Available from: https:\/\/www.nature.com\/articles\/s41408-021-00408-4","DOI":"10.1038\/s41408-021-00408-4"},{"key":"143_CR28","doi-asserted-by":"crossref","unstructured":"Pe\u010dinka L, Vlachov\u00e1 M, Mor\u00e1\u0148 L, Gregorov\u00e1 J, Porokh V, Kova\u010dovicov\u00e1 P et al. Improved Screening of Monoclonal Gammopathy Patients by MALDI-TOF Mass Spectrometry. J Am Soc Mass Spectrom [Internet]. 2023 Dec 6 [cited 2024 Oct 15];34(12):2646\u201353. Available from: https:\/\/pubs.acs.org\/doi\/10.1021\/jasms.3c00166","DOI":"10.1021\/jasms.3c00166"},{"key":"143_CR29","doi-asserted-by":"crossref","unstructured":"Vlachov\u00e1 M, Pe\u010dinka L, Gregorov\u00e1 J, Mor\u00e1\u0148 L, R\u016f\u017ei\u010dkov\u00e1 T, Kova\u010dovicov\u00e1 P et al. Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients. Sci Rep [Internet]. 2024 Aug 13 [cited 2024 Oct 15];14(1):18777. Available from: https:\/\/www.nature.com\/articles\/s41598-024-69408-1","DOI":"10.1038\/s41598-024-69408-1"},{"key":"143_CR30","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol [Internet]. 2021 Mar [cited 2024 Oct 30];32(3):309\u201322. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420431692","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"143_CR31","doi-asserted-by":"crossref","unstructured":"Kumar SK, Rajkumar V, Kyle RA, Van Duin M, Sonneveld P, Mateos MV et al. Multiple myeloma. Nat Rev Dis Primer [Internet]. 2017 Jul 20 [cited 2024 Jun 3];3(1):17046. Available from: https:\/\/www.nature.com\/articles\/nrdp201746","DOI":"10.1038\/nrdp.2017.46"},{"key":"143_CR32","doi-asserted-by":"crossref","unstructured":"Cliff ERS, Mohyuddin GR. Overall survival as a primary end point in multiple myeloma trials. Nat Rev Clin Oncol [Internet]. 2022 Sep [cited 2024 Oct 30];19(9):565\u20136. Available from: https:\/\/www.nature.com\/articles\/s41571-022-00665-7","DOI":"10.1038\/s41571-022-00665-7"},{"key":"143_CR33","doi-asserted-by":"crossref","unstructured":"Marinac CR, Ghobrial IM, Birmann BM, Soiffer J, Rebbeck TR. Dissecting racial disparities in multiple myeloma. Blood Cancer J [Internet]. 2020 Feb 17 [cited 2024 Jul 15];10(2):19. Available from: https:\/\/www.nature.com\/articles\/s41408-020-0284-7","DOI":"10.1038\/s41408-020-0284-7"},{"key":"143_CR34","doi-asserted-by":"crossref","unstructured":"Pu\u0142a A, Robak P, Jarych D, Mikulski D, Misiewicz M, Drozdz I et al. The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. Int J Mol Sci [Internet]. 2023 Feb 2 [cited 2024 Oct 30];24(3):2938. Available from: https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2938","DOI":"10.3390\/ijms24032938"},{"key":"143_CR35","doi-asserted-by":"publisher","unstructured":"Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica [Internet]. 2016 Apr [cited 2024 Oct 30];101(4):396\u2013406. Available from: http:\/\/www.haematologica.org\/lookup\/doi\/https:\/\/doi.org\/10.3324\/haematol.2015.129189","DOI":"10.3324\/haematol.2015.129189"},{"key":"143_CR36","doi-asserted-by":"crossref","unstructured":"Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia [Internet]. 2018 Feb [cited 2024 Oct 30];32(2):252\u201362. Available from: https:\/\/www.nature.com\/articles\/leu2017329","DOI":"10.1038\/leu.2017.329"},{"key":"143_CR37","doi-asserted-by":"crossref","unstructured":"Insenser M, Quintero A, De Lope S, \u00c1lvarez-Blasco F, Mart\u00ednez-Garc\u00eda M\u00c1, Luque-Ram\u00edrez M et al. Validation of circulating microRNAs miR-142-3p and miR-598-3p in women with polycystic ovary syndrome as potential diagnostic markers. Hum Reprod [Internet]. 2023 May 2 [cited 2024 Oct 30];38(5):951\u201360. Available from: https:\/\/academic.oup.com\/humrep\/article\/38\/5\/951\/7080093","DOI":"10.1093\/humrep\/dead043"},{"key":"143_CR38","first-page":"269","volume":"28","author":"X Lin","year":"2022","unstructured":"Lin X, Huang X, Wang L, Liu W. The long noncoding RNA MALAT1\/microRNA-598-3p axis regulates the proliferation and apoptosis of retinoblastoma cells through the PI3K\/AKT pathway. Mol Vis. 2022;28:269\u201379.","journal-title":"Mol Vis"},{"key":"143_CR39","doi-asserted-by":"publisher","unstructured":"Fu L, Li Z, Zhu J, Wang P, Fan G, Dai Y et al. Serum expression levels of microRNA-382-3p, \u2013\u2009598-3p, \u2013\u20091246 and \u2013\u2009184 in breast cancer patients. Oncol Lett [Internet]. 2016 Jul [cited 2024 Oct 30];12(1):269\u201374. Available from: https:\/\/www.spandidos-publications.com\/https:\/\/doi.org\/10.3892\/ol.2016.4582","DOI":"10.3892\/ol.2016.4582"},{"key":"143_CR40","doi-asserted-by":"publisher","unstructured":"Li K, Fang Y, Liao J, Duan J, Feng L, Luo X et al. Upregulation of miR\u2013598 promotes cell proliferation and cell cycle progression in human colorectal carcinoma by suppressing INPP5E expression. Mol Med Rep [Internet]. 2017 Dec 6 [cited 2024 Oct 30]; Available from: http:\/\/www.spandidos-publications.com\/https:\/\/doi.org\/10.3892\/mmr.2017.8207","DOI":"10.3892\/mmr.2017.8207"},{"key":"143_CR41","doi-asserted-by":"crossref","unstructured":"Qiang Z, Feng J, Wang C, Zheng M, Wen Z. MiR-598-3p functions as a tumor suppressor in pediatric T-cell acute lymphoblastic leukemia. Trop J Pharm Res [Internet]. 2022 Jan 17 [cited 2024 Oct 30];20(3):497\u2013503. Available from: https:\/\/www.ajol.info\/index.php\/tjpr\/article\/view\/220126","DOI":"10.4314\/tjpr.v20i3.8"},{"key":"143_CR42","doi-asserted-by":"crossref","unstructured":"Chen X, Xiong X, Cui D, Yang F, Wei D, Li H et al. DEPTOR is an in vivo tumor suppressor that inhibits prostate tumorigenesis via the inactivation of mTORC1\/2 signals. Oncogene [Internet]. 2020 Feb 13 [cited 2024 Oct 30];39(7):1557\u201371. Available from: https:\/\/www.nature.com\/articles\/s41388-019-1085-y","DOI":"10.1038\/s41388-019-1085-y"},{"key":"143_CR43","doi-asserted-by":"publisher","unstructured":"Quwaider D, Corchete LA, Misiewicz-Krzeminska I, Sarasquete ME, P\u00e9rez JJ, Krzeminski P et al. DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. J Hematol OncolJ Hematol Oncol [Internet]. 2017 Dec [cited 2024 Oct 30];10(1):92. Available from: http:\/\/jhoonline.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s13045-017-0461-8","DOI":"10.1186\/s13045-017-0461-8"},{"key":"143_CR44","doi-asserted-by":"crossref","unstructured":"Kallingal A, Thankachan S, Venkatesh T, Kabbekodu SP, Suresh PS. Role of miR-15b\/16\u20132 cluster network in endometrial cancer: An in silico pathway and prognostic analysis. Meta Gene [Internet]. 2022 Feb [cited 2024 Oct 30];31:101018. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214540022000093","DOI":"10.1016\/j.mgene.2022.101018"},{"key":"143_CR45","doi-asserted-by":"crossref","unstructured":"Lovat F, Fassan M, Gasparini P, Rizzotto L, Cascione L, Pizzi M et al. miR-15b\/16\u2009\u2013\u20092 deletion promotes B-cell malignancies. Proc Natl Acad Sci [Internet]. 2015 Sep 15 [cited 2024 Oct 30];112(37):11636\u201341. Available from: https:\/\/pnas.doi\/full\/10.1073\/pnas.1514954112","DOI":"10.1073\/pnas.1514954112"},{"key":"143_CR46","doi-asserted-by":"publisher","unstructured":"Duan L, Zhao H, Xiong Y, Tang X, Yang Y, Hu Z et al. miR-16-2* Interferes with WNT5A to Regulate Osteogenesis of Mesenchymal Stem Cells. Cell Physiol Biochem [Internet]. 2018 [cited 2024 Oct 30];51(3):1087\u2013102. Available from: https:\/\/karger.com\/CPB\/article\/doi\/https:\/\/doi.org\/10.1159\/000495489","DOI":"10.1159\/000495489"},{"key":"143_CR47","doi-asserted-by":"crossref","unstructured":"Frenquelli M, Caridi N, Antonini E, Storti F, Vigan\u00f2 V, Gaviraghi M et al. The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation. Leukemia [Internet]. 2020 Jan [cited 2024 Oct 30];34(1):257\u201370. Available from: https:\/\/www.nature.com\/articles\/s41375-019-0486-9","DOI":"10.1038\/s41375-019-0486-9"},{"issue":"5","key":"143_CR48","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1365-2141.2009.08009.x","volume":"148","author":"YW Qiang","year":"2010","unstructured":"Qiang YW, Chen Y, Brown N, Hu B, Epstein J, Barlogie B, et al. Characterization of Wnt\/beta-catenin signalling in osteoclasts in multiple myeloma. Br J Haematol. 2010;148(5):726\u201338.","journal-title":"Br J Haematol"},{"key":"143_CR49","doi-asserted-by":"crossref","unstructured":"Robak P, Dr\u00f3\u017cd\u017c I, Jarych D, Mikulski D, W\u0119g\u0142owska E, Siemieniuk-Ry\u015b M et al. The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients. Cancers [Internet]. 2020 Sep 9 [cited 2024 Oct 30];12(9):2569. Available from: https:\/\/www.mdpi.com\/2072-6694\/12\/9\/2569","DOI":"10.3390\/cancers12092569"},{"key":"143_CR50","doi-asserted-by":"crossref","unstructured":"Katiyar A, Kaur G, Rani L, Jena L, Singh H, Kumar L et al. Genome-wide identification of potential biomarkers in multiple myeloma using meta-analysis of mRNA and miRNA expression data. Sci Rep [Internet]. 2021 May 26 [cited 2024 Oct 30];11(1):10957. Available from: https:\/\/www.nature.com\/articles\/s41598-021-90424-y","DOI":"10.1038\/s41598-021-90424-y"},{"key":"143_CR51","doi-asserted-by":"publisher","unstructured":"Du Y, Miao Z, Wang K, Lv Y, Qiu L, Guo L. Expression levels and clinical values of miR-92b-3p in breast cancer. World J Surg Oncol [Internet]. 2021 Dec [cited 2024 Oct 30];19(1):239. Available from: https:\/\/wjso.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12957-021-02347-7","DOI":"10.1186\/s12957-021-02347-7"},{"key":"143_CR52","doi-asserted-by":"publisher","unstructured":"Gong L, Ren M, Lv Z, Yang Y, Wang Z. miR-92b-3p Promotes Colorectal Carcinoma Cell Proliferation, Invasion, and Migration by Inhibiting FBXW7 In Vitro and In Vivo. DNA Cell Biol [Internet]. 2018 May [cited 2024 Oct 30];37(5):501\u201311. Available from: http:\/\/www.liebertpub.com\/doi\/https:\/\/doi.org\/10.1089\/dna.2017.4080","DOI":"10.1089\/dna.2017.4080"},{"key":"143_CR53","doi-asserted-by":"publisher","unstructured":"Long M, Zhan M, Xu S, Yang R, Chen W, Zhang S et al. miR-92b-3p acts as a tumor suppressor by targeting Gabra3 in pancreatic cancer. Mol Cancer [Internet]. 2017 Dec [cited 2024 Oct 30];16(1):167. Available from: http:\/\/molecular-cancer.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12943-017-0723-7","DOI":"10.1186\/s12943-017-0723-7"},{"key":"143_CR54","doi-asserted-by":"publisher","unstructured":"Sun Y, Feng Y, Zhang G, Xu Y. The endonuclease APE1 processes miR-92b formation, thereby regulating expression of the tumor suppressor LDLR in cervical cancer cells. Ther Adv Med Oncol [Internet]. 2019 Jan [cited 2024 Oct 30];11:1758835919855859. Available from: https:\/\/journals.sagepub.com\/doi\/https:\/\/doi.org\/10.1177\/1758835919855859","DOI":"10.1177\/1758835919855859"},{"key":"143_CR55","doi-asserted-by":"publisher","unstructured":"Wang C, Uemura M, Tomiyama E, Matsushita M, Koh Y, Nakano K et al. MicroRNA-92b\u20103p is a prognostic oncomiR that targets TSC1 in clear cell renal cell carcinoma. Cancer Sci [Internet]. 2020 Apr [cited 2024 Oct 30];111(4):1146\u201355. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/cas.14325","DOI":"10.1111\/cas.14325"},{"key":"143_CR56","doi-asserted-by":"publisher","unstructured":"Wang G, Cheng B, Jia R, Tan B, Liu W. Altered expression of microRNA\u201392b\u20133p predicts survival outcomes of patients with prostate cancer and functions as an oncogene in tumor progression. Oncol Lett [Internet]. 2020 Nov 3 [cited 2024 Oct 30];21(1):1\u20131. Available from: http:\/\/www.spandidos-publications.com\/https:\/\/doi.org\/10.3892\/ol.2020.12265","DOI":"10.3892\/ol.2020.12265"},{"issue":"6","key":"143_CR57","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1364\/BOE.421333","volume":"12","author":"X Chen","year":"2021","unstructured":"Chen X, Zhang Y, Li X, Yang Z, Liu A, Yu X. Diagnosis and staging of multiple myeloma using serum-based laser-induced breakdown spectroscopy combined with machine learning methods. Biomed Opt Express. 2021;12(6):3584\u201396.","journal-title":"Biomed Opt Express"},{"issue":"10","key":"143_CR58","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1038\/s41375-021-01286-2","volume":"35","author":"A Mosquera Orgueira","year":"2021","unstructured":"Mosquera Orgueira A, Gonz\u00e1lez P\u00e9rez MS, D\u00edaz Arias J\u00c1, Antelo Rodr\u00edguez B, Alonso Vence N, Benda\u00f1a L\u00f3pez \u00c1, et al. Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data. Leukemia. 2021;35(10):2924\u201335.","journal-title":"Leukemia"},{"key":"143_CR59","doi-asserted-by":"publisher","first-page":"601699","DOI":"10.3389\/fonc.2021.601699","volume":"11","author":"X Xiong","year":"2021","unstructured":"Xiong X, Wang J, Hu S, Dai Y, Zhang Y, Hu C. Differentiating between multiple myeloma and metastasis subtypes of lumbar vertebra lesions using machine learning-based Radiomics. Front Oncol. 2021;11:601699.","journal-title":"Front Oncol"},{"key":"143_CR60","doi-asserted-by":"publisher","first-page":"608191","DOI":"10.3389\/fonc.2021.608191","volume":"11","author":"W Yan","year":"2021","unstructured":"Yan W, Shi H, He T, Chen J, Wang C, Liao A, et al. Employment of Artificial Intelligence Based on Routine Laboratory Results for the early diagnosis of multiple myeloma. Front Oncol. 2021;11:608191.","journal-title":"Front Oncol"},{"key":"143_CR61","doi-asserted-by":"crossref","unstructured":"Han X, Li D, Wang S, Lin Y, Liu Y, Lin L et al. Serum amino acids quantification by plasmonic colloidosome-coupled MALDI-TOF MS for triple-negative breast cancer diagnosis. Mater Today Bio [Internet]. 2022 Dec [cited 2024 Dec 4];17:100486. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590006422002848","DOI":"10.1016\/j.mtbio.2022.100486"},{"key":"143_CR62","doi-asserted-by":"crossref","unstructured":"Lai X, Guo K, Huang W, Su Y, Chen S, Li Q et al. Combining MALDI-MS with machine learning for metabolomic characterization of lung cancer patient sera. Anal Methods [Internet]. 2022 [cited 2024 Dec 4];14(5):499\u2013507. Available from: https:\/\/xlink.rsc.org\/?DOI=D1AY01940F","DOI":"10.1039\/D1AY01940F"},{"key":"143_CR63","doi-asserted-by":"crossref","unstructured":"Lee JW, Lee K, Ahn SH, Son BH, Ko BS, Kim HJ et al. Potential of MALDI-TOF-based serum N-glycan analysis for the diagnosis and surveillance of breast cancer. Sci Rep [Internet]. 2020 Nov 5 [cited 2024 Dec 4];10(1):19136. Available from: https:\/\/www.nature.com\/articles\/s41598-020-76195-y","DOI":"10.1038\/s41598-020-76195-y"},{"key":"143_CR64","doi-asserted-by":"crossref","unstructured":"Bhattacharyya S, Epstein J, Suva LJ. Biomarkers that Discriminate Multiple Myeloma Patients with or without Skeletal Involvement Detected Using SELDI-TOF Mass Spectrometry and Statistical and Machine Learning Tools. Dis Markers [Internet]. 2006 Jan [cited 2024 Oct 30];22(4):245\u201355. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2006\/728296","DOI":"10.1155\/2006\/728296"},{"key":"143_CR65","doi-asserted-by":"publisher","unstructured":"He A, Bai J, Huang C, Yang J, Zhang W, Wang J et al. Detection of serum tumor markers in multiple myeloma using the CLINPROT system. Int J Hematol [Internet]. 2012 Jun [cited 2024 Oct 30];95(6):668\u201374. Available from: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s12185-012-1080-3","DOI":"10.1007\/s12185-012-1080-3"},{"key":"143_CR66","doi-asserted-by":"publisher","unstructured":"Wang Q, Li Y, Liang Y, Hu C, Zhai Y, Zhao G et al. Construction of A Multiple Myeloma Diagnostic Model by Magnetic Bead-Based MALDI\u2010TOF Mass Spectrometry of Serum and Pattern Recognition Software. Anat Rec [Internet]. 2009 Apr [cited 2024 Oct 30];292(4):604\u201310. Available from: https:\/\/anatomypubs.onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/ar.20871","DOI":"10.1002\/ar.20871"},{"issue":"3","key":"143_CR67","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3324\/haematol.2013.093500","volume":"99","author":"L Kubiczkov\u00e1","year":"2014","unstructured":"Kubiczkov\u00e1 L, Kryukov F, Slab\u00fd O, Dementyeva E, Jarkovsk\u00fd J, Nekvindov\u00e1 J, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2014;99(3):511\u20138.","journal-title":"Haematologica"},{"key":"143_CR68","doi-asserted-by":"publisher","unstructured":"Sedlarikova L, Bollova B, Radova L, Brozova L, Jarkovsky J, Almasi M et al. Circulating exosomal long noncoding RNA PRINS\u2014First findings in monoclonal gammopathies. Hematol Oncol [Internet]. 2018 Dec [cited 2024 Oct 29];36(5):786\u201391. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/hon.2554","DOI":"10.1002\/hon.2554"},{"key":"143_CR69","doi-asserted-by":"publisher","unstructured":"Patil AH, Halushka MK. miRge3.0: a comprehensive microRNA and tRF sequencing analysis pipeline. NAR Genomics Bioinforma [Internet]. 2021 Jun 23 [cited 2024 Oct 21];3(3):lqab068. Available from: https:\/\/academic.oup.com\/nargab\/article\/doi\/https:\/\/doi.org\/10.1093\/nargab\/lqab068\/6325159","DOI":"10.1093\/nargab\/lqab068\/6325159"},{"key":"143_CR70","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing [Internet]. Vienna, Austria. 2020. Available from: https:\/\/www.R-project.org\/"},{"key":"143_CR71","doi-asserted-by":"crossref","unstructured":"McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res [Internet]. 2012 May 1 [cited 2024 Oct 21];40(10):4288\u201397. Available from: https:\/\/academic.oup.com\/nar\/article\/40\/10\/4288\/2411520","DOI":"10.1093\/nar\/gks042"},{"key":"143_CR72","doi-asserted-by":"crossref","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics [Internet]. 2010 Jan 1 [cited 2024 Oct 21];26(1):139\u201340. Available from: https:\/\/academic.oup.com\/bioinformatics\/article\/26\/1\/139\/182458","DOI":"10.1093\/bioinformatics\/btp616"},{"key":"143_CR73","doi-asserted-by":"crossref","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res [Internet]. 2015 Apr 20 [cited 2024 Oct 21];43(7):e47\u2013e47. Available from: http:\/\/academic.oup.com\/nar\/article\/43\/7\/e47\/2414268\/limma-powers-differential-expression-analyses-for","DOI":"10.1093\/nar\/gkv007"},{"key":"143_CR74","doi-asserted-by":"crossref","unstructured":"Kuhn M. Building Predictive Models in R Using the caret Package. J Stat Softw [Internet]. 2008 [cited 2024 Dec 9];28(5). Available from: http:\/\/www.jstatsoft.org\/v28\/i05\/","DOI":"10.18637\/jss.v028.i05"},{"key":"143_CR75","doi-asserted-by":"crossref","unstructured":"Gibb S, Strimmer K. MALDIquant: a versatile R package for the analysis of mass spectrometry data. Bioinformatics [Internet]. 2012 Sep 1 [cited 2024 Dec 9];28(17):2270\u20131. Available from: https:\/\/academic.oup.com\/bioinformatics\/article\/28\/17\/2270\/246552","DOI":"10.1093\/bioinformatics\/bts447"},{"key":"143_CR76","doi-asserted-by":"crossref","unstructured":"Pe\u010dinka L, Mor\u00e1\u0148 L, Kova\u010dovicov\u00e1 P, Meloni F, Havel J, Pivetta T et al. Intact cell mass spectrometry coupled with machine learning reveals minute changes induced by single gene silencing. Heliyon [Internet]. 2024 May [cited 2024 Dec 4];10(9):e29936. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402405967X","DOI":"10.1016\/j.heliyon.2024.e29936"},{"key":"143_CR77","doi-asserted-by":"crossref","unstructured":"Th\u00e9venot EA, Roux A, Xu Y, Ezan E, Junot C. Analysis of the Human Adult Urinary Metabolome Variations with Age, Body Mass Index, and Gender by Implementing a Comprehensive Workflow for Univariate and OPLS Statistical Analyses. J Proteome Res [Internet]. 2015 Aug 7 [cited 2024 Dec 9];14(8):3322\u201335. Available from: https:\/\/pubs.acs.doi\/10.1021\/acs.jproteome.5b00354","DOI":"10.1021\/acs.jproteome.5b00354"}],"container-title":["Cell Division"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13008-025-00143-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13008-025-00143-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13008-025-00143-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T06:12:29Z","timestamp":1738131149000},"score":1,"resource":{"primary":{"URL":"https:\/\/celldiv.biomedcentral.com\/articles\/10.1186\/s13008-025-00143-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["143"],"URL":"https:\/\/doi.org\/10.1186\/s13008-025-00143-3","relation":{},"ISSN":["1747-1028"],"issn-type":[{"value":"1747-1028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the University Hospital Brno Ethics Committee. All patients included in this study signed an informed consent form approved by the hospital\u2019s Ethics committee in accordance with the current Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}